stars 1 stars 2 stars 3

Established in 2001, MediWound is focused on developing, manufacturing and globally commercializing innovative products that address unmet needs in the fields of severe burn and chronic wound management. MediWound's goal is to provide healthcare professionals and patients with its innovative, burn wound eschar removal agent, NexoBrid™. NexoBrid™, is indicated in Europe for removal of eschar in adults with deep partial- and full-thickness thermal burns. NexoBrid™ successfully completed clinical development in hospitalized burn wounds and was launched throughout Europe. MediWound operates a cGMP manufacturing facility for sterile pharmaceutical products that meets high quality requirements

MediWound Ltd. Questions

The MediWound Ltd. annual revenue was $5 million in 2026.

The NAICS codes for MediWound Ltd. are [32, 3254, 325].

The SIC codes for MediWound Ltd. are [28, 80, 283].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users